2 results
Approved WMOCompleted
To increase progression-free survival at 3 months.
Approved WMOCompleted
Primary Objective:The primary objective is to assess the safety and tolerability of BMS-986179 administered alone and/or in combination with nivolumab.Secondary objectives:* To characterize the PD activity of BMS-986179 administered alone and in…